Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Person › Details

Thérèse Croughs (Neovacs S.A. (Euronext Growth Paris: ALNEV))

Croughs, Thérèse (Neovacs 201509 CMO)

 

Organisation Organisation Neovacs S.A. (Euronext Growth Paris: ALNEV)
  Group Neovacs (Group)
Products Product IFNalpha-Kinoid (IFNa-Kinoïd)
  Product 2 drug development
     

Neovacs S.A.. (9/9/15). "Press Release: Neovacs Confirms Potent and Long-lasting Biological Activity of IFNa-Kinoid 4 Years after Patient Dosing in Phase I/IIa Trial". Paris & Boston, MA.

Company presented extended follow-up data on IFNa-Kinoid at 11th international congress on Lupus


NEOVACS (Alternext Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that it presented extended follow-up data from the Phase I/IIa clinical trial of IFNa-Kinoid during Lupus 2015, the 11th International Congress on Systemic Lupus Erythematosus (SLE), which took place from 2 to 6 September 2015 in Vienna, Austria.

"The results we presented at Lupus 2015 show that our lead product candidate induces a lasting, polyclonal, neutralizing anti-IFNa response in SLE patients. This is an extremely positive sign as we are about to launch the Phase IIb trial of IFNa-Kinoid in SLE" commented Thérèse Croughs, M.D., Chief Medical Officer of Neovacs.

This new data1, collected as part of the Phase I/IIa extended follow-up study of six IFNa-Kinoid-treated patients, demonstrates that anti-IFNa neutralizing antibodies generated by IFNa-Kinoid continue to be present four years after the first immunization, and maintain the normalization of the IFNa signature. This confirms previously reported results2.

The study also highlights the association between anti-IFNa neutralizing antibodies and the decreased expression of induced genes associated with B cell activation. B-cell activation, like the IFNa-signature, has been linked to the pathogenesis of SLE lupus3.

Follow up data from the Phase I/IIa clinical trial was presented in the poster "IFNa-kinoid (IFN-K) induces neutralizing anti-IFNa antibodies that decrease the expression of IFN-induced and B cell activation associated transcripts : Analysis of extended follow-up data from the IFN-K Phase I/IIa study"1 on Friday, September 4, 2015 in Vienna.


1 J. Ducreux, et Al, Lupus 2015, Poster Session P04 Treatment.

2 Neovacs has previously reported the strong level of biological activity of IFNa-Kinoid at 6 months after first immunization with IFNa-Kinoid. See Bernard Lauwerys et al., Down-Regulation of Interferon Signature in Systemic Lupus Erythematosus Patients by Active Immunization With Interferon -Kinoid, Arthritis & Rheumatism Vol. 65, No. 2, February 2013.

3 Kiefer K, Oropallo MA, Cancro MP, et al. Role of type I interferons in the activation of autoreactive B cells. Immunol Cell Biol 2012.


About the extended follow-up study of Phase I/IIa of IFNa-Kinoid in Lupus

Data was collected on six IFNa-Kinoid-treated patients included in the Phase I/IIa clinical trial of IFNa-Kinoid in SLE or lupus. Five of the six patients presented a positive IFN-signature at baseline. The same level of normalization of the IFN-signature as previously reported was observed in two out of five patients who developed neutralizing antibodies. Correlation in the increase of C3 serum level and neutralizing anti-IFNa antibodies also persisted in the same two patients, confirming previously reported results.


About Neovacs

Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNa-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, please visit www.neovacs.fr


Contacts

NEOVACS - Investor Relations
Nathalie Trépo
+33 (0)1 53 10 93 00
ntrepo@neovacs.com

Investor Relations / Financial Communications - NewCap
Valentine Brouchot / Pierre Laurent
+33 (0)1 44 71 94 94
neovacs@newcap.fr

Investor Relations / Financial Communications Germany - MC Services
Raimund Gabriel
+49-89-210228-30
raimund.gabriel@mc-services.eu

Press / U.S. Inquiries - The Ruth Group
Melanie Sollid-Penton
1.646.536.7023
msollid@theruthgroup.com

   
Record changed: 2018-02-20

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px


More documents for Thérèse Croughs


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 600x60px




» top